Pharmacokinetic study of STN1012600 ophthalmic solution in healthy adult males volunteers
Completed
- Conditions
- open angle glaucoma (OAG) or ocular hypertension (OHT)
- Registration Number
- jRCT2051230035
- Lead Sponsor
- Santen pharmaceutical co.,ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Male
- Target Recruitment
- 8
Inclusion Criteria
Subjects who can comply with scheduled visits and the examination and observation as specified in the clinical study protocol
Exclusion Criteria
1)Subjects have a disease and/or abnormal laboratory value which is considered inappropriate from safety evaluation perspective 2)Subjects who are inappropriate as participants in this study in the opinion of the investigator or sub investigator
Study & Design
- Study Type
- Interventional
- Study Design
- single assignment
- Primary Outcome Measures
Name Time Method - Plasma pharmacokinetics
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What is the mechanism of action of STN1012600 in reducing intraocular pressure for open angle glaucoma and ocular hypertension?
How does the pharmacokinetics of STN10102600 compare to other prostaglandin analogs used in open angle glaucoma treatment?
Are there specific ocular biomarkers that correlate with STN1012600 efficacy in patients with ocular hypertension?
What are the potential adverse events associated with STN1012600 ophthalmic solution and how are they managed in clinical trials?
What other compounds or combination therapies is Santen Pharmaceutical developing for open angle glaucoma compared to STN1012600?